Gold prices fall as geopolitical tensions ease; U.S. CPI looms
Investing.com - TD Cowen lowered its price target on Tandem Diabetes Care (NASDAQ:TNDM) stock to $20.00 from $27.00 on Thursday, while maintaining a Buy rating on the shares. The stock, currently trading at $10.93, has fallen over 60% year-to-date and is trading near its 52-week low, according to InvestingPro data.
The price target reduction follows Tandem’s second-quarter report, in which the company cut its 2025 U.S. sales guidance to $700 million from the previous range of $725 million to $730 million. Despite current challenges, the company maintains a healthy gross profit margin of 52.55% and a strong current ratio of 2.44, indicating solid short-term liquidity.
Tandem cited its ongoing commercial transformation and increased U.S. competition as key factors behind the guidance reduction, noting these challenges would likely cause "pausing" in the second half of 2025.
TD Cowen indicated that while it continues to view Tandem’s portfolio and pipeline favorably, especially over the longer term, concerns about U.S. competition are expected to create a near-term overhang on the stock.
The research firm expects these competitive pressures to impact investor sentiment toward Tandem Diabetes Care shares throughout the remainder of 2025.
In other recent news, Tandem Diabetes Care reported its second-quarter 2025 earnings, which revealed a larger-than-expected loss per share. The company’s earnings per share (EPS) registered a loss of $0.78, falling short of the anticipated $0.40. Despite this, the company experienced a revenue surprise, with international sales outperforming expectations, although U.S. sales did not meet projections. Following these results, Barclays (LON:BARC) adjusted its price target for Tandem Diabetes Care to $51 from $53, while maintaining an Overweight rating on the stock. These developments reflect the mixed performance of the company in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.